Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Biosimilar — Net revenue

Other product segments

Subtotal dosage forms
$482.3M+11.8%
Oral solid
$175.17M-1.7%
Subtotal therapeutic classes
$149.3M+17.1%
Central nervous system
$95.34M+14.3%
Distribution
$86.93M-12.8%
Other dosage forms
$81.59M+19.7%
Transdermal
$67.04M+64.7%
Auto-Injector
$62.21M-6.6%
Injectable
$56.78M+63.9%
Government label
$50.21M+10.5%
Hormonal / allergy
$42.1M+18.9%
Institutional
$12.11M+19.5%
Other therapeutic classes
$11.85M+36.2%
Oral liquid
$10.37M-42.0%
International
$7.61M+300%
License agreement
$0-100%

Similar metrics at other companies

Installed Building Products logo
IBPNet revenue, Installation — Net revenue
$710.7M-0.7%
Marqeta logo
MQPlatform services revenue, net — Net revenue
$156.23M+18.5%
Visa logo
VOther revenue — Net revenue
$1.5B+45.5%
Visa logo
VService revenue — Net revenue
$4.92B+13.7%
Cavco Industries logo
CVCODelivery, setup and other revenues — Net revenue
$23.21M-15.9%
Marqeta logo
MQOther services revenue — Net revenue
$9.57M+32.8%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.89B+129%
Enterprise value$8.34B+77.4%
P/E37.5×-726×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×—
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Transdermal67,03840,710141,00183,773
Auto-Injector62,21466,594104,126114,754
Injectable56,78334,646106,72169,434
Biosimilar29,12825,24851,42953,788
Oral liquid10,37117,87922,46341,427
Other dosage forms (1)81,59468,185128,206124,607
Subtotal dosage forms482,300431,524900,218844,998
International7,6131,90112,9323,135

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported biosimilar — net revenue of $29.13M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue increased by 15.4% year-over-year, from $25.25M to $29.13M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue has grown at a 213.9% compound annual growth rate (CAGR), from $3.24M to $100.23M.
What does biosimilar — net revenue mean?
This metric represents the total gross sales of biosimilar pharmaceutical products minus returns, rebates, and other revenue deductions within a specific reporting period. It serves as a key indicator of the company's market penetration and commercial success in the highly regulated, complex biologics space. Tracking this revenue stream helps investors evaluate the growth trajectory and competitive positioning of the company's high-barrier-to-entry product portfolio.

Ask your AI about Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude